11C-verapamil to assess P-gp function in human brain during aging, depression and neurodegenerative disease

Current Topics in Medicinal Chemistry

Volumn 10, Issue 17, 2010, Pages 1775-1784

  Bartels, A L ^a   de Klerk, O L ^a   Kortekaas, R ^a   de Vries, J J ^a   Leenders, K L ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Ageing; Alzheimer's disease; Blood brain barrier; Depression; P glycoprotein; Parkinson's disease; Positron emission tomography (PET); Verapamil

Indexed keywords

CARBON 11; GLYCOPROTEIN P; VERAPAMIL; CARBON;

AGING; ALZHEIMER DISEASE; ARTICLE; BLOOD BRAIN BARRIER; DEGENERATIVE DISEASE; DEPRESSION; DRUG UPTAKE; HUMAN; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PROTEIN FUNCTION; BRAIN DISEASE; CHEMISTRY; METABOLISM; PATHOPHYSIOLOGY; REVIEW; SCINTISCANNING;

AGING; BLOOD-BRAIN BARRIER; BRAIN DISEASES; CARBON RADIOISOTOPES; DEPRESSIVE DISORDER; HUMANS; NEURODEGENERATIVE DISEASES; P-GLYCOPROTEIN; POSITRON-EMISSION TOMOGRAPHY; VERAPAMIL;

EID: 77957997644     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802610792928059     Document Type: Article

References (110)

1. Higgins, C.F. Abc transporters - from microorganisms to man. Ann. Rev. Cell Biol., 1992, 8, 67-113.
2. Cordon-Cardo, C.; O'Brien, J.P.; Casals, D.; Rittman-Grauer, L.; Biedler, J. L.; Melamed, M.R.; Bertino, J.R. multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood- brain barrier sides. Proc. Natl. Acad. Sci. USA, 1989, 86, 695-698.
3. Demeule, M.; Labelle, M.; Regina, A.; Berthelet, F.; Beliveau, R. Isolation of endothelial cells from brain, lung, and kidney: Expression of the multidrug resistance P-glycoprotein isoforms. Biochem. Biophy. Res. Commun., 2001, 281 (3), 827-834.
4. Aller, S.G.; Yu, J.; Ward, A.; Weng, Y.; Chittaboina, S.; Zhuo, R.; Harrell, P.M.; Trinh, Y.T.; Zhang, Q.; Urbatsch, I.L.; Chang, G. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science, 2009, 323(5922), 1718-1722.
5. Bendayan, R.; Ronaldson, P.T.; Gingras, D.; Bendayan, M. In situ localization of P-glycoprotein (ABCB1) in human and rat brain. J. Histochem. Cytochem., 2006, 54(10), 1159-167.
6. de Lange, E.C.M. Potential role of ABC transporters as a detoxification system at the blood-CSF barrier. Adv. Drug Deliv. Rev., 2004, 56(12), 1793-809.
7. Kim, R.B. Drugs as P-glycoprotein substrates, inhibitors, and inducers. Drug Metab. Rev., 2002, 34(1-2), 47-54.
8. Vautier, S.; Fernandez, C. ABCB1: the role in Parkinson's disease and pharmacokinetics of antiparkinsonian drugs. Expert. Opin. Drug Metab. Toxicol., 2009, 5(11), 1349-158.
9. Gerhard, A.; Pavese, N.; Hotton, G.; Turkheimer, F.; Es, M.; Hammers, A.; Eggert, K.; Oertel, W.; Banati, R.B.; Brooks, D.J. In vivo imaging of microglial activation with [C-11](R)- PK11195 PET in idiopathic Parkinson's disease. Neurobiol. Dis., 2006, 21(2), 404-412.
10. Mcgeer, P.L.; Mcgeer, E.G. Glial cell reactions in neurodegenerative diseases: Pathophysiology and therapeutic interventions. Alzheimer Dis. Assoc. Disord., 1998, 12, S1-S6.
11. Mcgeer, P.L.; Mcgeer, E.G. Inflammation and neurodegeneration in Parkinson's disease. Parkinsonism Relat. Disord., 2004, 10, S3-S7.
12. Langford, D.; Grigorian, A.; Hurford, R.; Adame, A.; Ellis, R.J.; Hansen, L.; Masliah, E. Altered P-glycoprotein expression in AIDS patients with HIV encephalitis. J. Neuropathol. Exp. Neurol., 2004, 63(10), 1038-1047.
13. Minghetti, L. Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases. J. Neuropathol. Exp. Neurol., 2004, 63(9), 901-910.
14. Hayley, S.; Poulter, M.O.; Merali, Z.; Anisman, H. The patho-genesis of clinical depression: stressorand cytokine-induced alterations of neuroplasticity. Neuroscience, 2005, 135(3), 659-678.
15. Fernandez, C.; Buyse, M.; German-Fattal, M.; Gimenez, F. Influence of the pro-inflammatory cytokines on P-glycoprotein expression and functionality. J. Pharm. Pharm. Sci., 2004, 7(3), 359-371.
16. Mcrae, M.P.; Brouwer, K.L.R.; Kashuba, A.D.M. Cytokine regulation of P-glycoprotein. Drug Metab. Rev., 2003, 35(1), 19-33.
17. Bauer, B.; Hartz, A.M.; Miller, D.S. Tumor necrosis factor alpha and endothelin-1 increase P-glycoprotein expression and transport activity at the blood-brain barrier. Mol. Pharmacol., 2007, 71(3), 667-675.
18. Hartz, A.M.S.; Bauer, B.; Fricker, G.; Miller, D.S. Rapid regulation of P-glycoprotein at the blood-brain barrier by endothelin-1. Mol. Pharmacol. 2004, 66(3), 387-394.
19. Hartz, A.M.S.; Bauer, B.; Fricker, G.; Miller, D.S. Rapid modulation of p-glycoprotein-mediated transport at the blood-brain barrier by tumor necrosis factor-alpha and lipopolysaccharide. Mol. Pharmacol., 2006, 69(2), 462-470.
20. Roberts, D.J.; Goralski, K.B. A critical overview of the influence of inflammation and infection on P-glycoprotein expression and activity in the brain. Expert. Opin. Drug. Metab. Toxicol. 2008, 4(10), 1245-1264.
21. Elsinga, P.H.; Hendrikse, N.H.; Bart, J.; van Waarde, A.; Vaalburg, W. Positron emission tomography studies on binding of central nervous system drugs and P-glycoprotein function in the rodent brain. Mol. Imaging. Biol., 2005, 7(1), 37-44.
22. Hendrikse, N.H.; De Vries, E.G.E.; Eriks-Fluks, L.; Van der Graaf, W.T.A.; Hospers, G.A.P.; Willemsen, A.T.M.; Vaalburg, W.; Franssen, E.J.F. A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier. Cancer Res., 1999, 59(10), 2411-2416.
23. Seneca, N.; Zoghbi, S.S.; Liow, J.S.; Kreisl, W.; Herscovitch, P.; Jenko, K.; Gladding, R.L.; Taku, A.; Pike, V.W.; Innis, R.B. Human brain imaging and radiation dosimetry of 11C-N-desmethylloperamide, a PET radiotracer to measure the function of P-glycoprotein. J. Nucl. Med., 2009, 50(5), 807-813.
24. Sasongko, L.; Link, J.M.; Muzi, M.; Mankoff, D.A.; Yang, X.; Collier, A.C.; Shoner, S.C.; Unadkat, J.D. Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography. Clin. Pharmacol. Ther., 2005, 77(6), 503-514.
25. Hendrikse, N.H.; Vaalburg, W.; De Vries, E.G.; Van der Graaf, W.T.; Willemsen, A.T. Quantification of in-vivo P-glycoprotein facilitated transport in the blood-brain barrier. J. Nucl. Med., 1999, 40(5), 261P-262P.
26. Hendrikse, N.H.; Bart, J.; De Vries, E.G.E.; Groen, H.J.M.; Van der Graaf, W.T.A.; Vaalburg, W. P-glycoprotein at the blood-brain barrier and analysis of drug transport with positron-emission tomography. J. Clin. Pharmacol., 2001, 48S-54S.
27. Lubberink, M.; Luurtsema, G.; van Berckel, B.N.; Boellaard, R.; Toornvliet, R.; Windhorst, A.D.; Franssen, E.J.; Lammertsma, A.A. Evaluation of tracer kinetic models for quantification of P-glycoprotein function using (R)-[11C]verapamil and PET. J. Cereb. Blood Flow Metab., 2007, 27(2), 424-433.
28. Takano, A.; Kusuhara, H.; Suhara, T.; Ieiri, I.; Morimoto, T.; Lee, Y.J.; Maeda, J.; Ikoma, Y.; Ito, H.; Suzuki, K.; Sugiyama, Y. Evaluation of in vivo P-glycoprotein function at the blood-brain barrier among MDR1 gene polymorphisms by using 11C-verapamil. J. Nucl. Med., 2006, 47(9), 1427-1433.
29. Bauer, M.; Karch, R.; Neumann, F.; Abrahim, A.; Wagner, C.C.; Kletter, K.; Muller, M.; Zeitlinger, M.; Langer, O. Age dependency of cerebral P-gp function measured with (R)-[11C] verapamil and PET. Eur. J. Clin. Pharmacol., 2009, 65(9), 941-946.
30. van Waarde, A.; Ramakrishnan, N.K.; Rybczynska, A.A.; Elsinga, P.H.; Berardi, F.; de Jong, J.R.; Kwizera, C.; Perrone, R.; Cantore, M.; Sijbesma, J.W.; Dierckx, R.A.; Colabufo, N.A. Synthesis and preclinical evaluation of novel PET probes for P-glycoprotein function and expression. J. Med. Chem., 2009, 52(14), 4524-4532.
31. Wagner, C.C.; Bauer, M.; Karch, R.; Feurstein, T.; Kopp, S.; Chiba, P.; Kletter, K.; Loscher, W.; Muller, M.; Zeitlinger, M.; Langer, O. A pilot study to assess the efficacy of tariquidar to inhibit P-glycoprotein at the human blood-brain barrier with (R)-11C- verapamil and PET. J. Nucl.Med., 2009, 50(12), 1954-1961.
32. Bart, J.; Willemsen, A.T.M.; Groen, H.J.M.; Van der Graaf, W.T.A.; Wegman, T.D.; Vaalburg, W.; De Vries, E.G.E.; Hendrikse, N.H. Quantitative assessment of P-glycoprotein function in the rat blood-brain barrier by distribution volume of [C-11]verapamil measured with PET. Neuroimage, 2003, 20(3), 1775-1782.
33. Bartels, A.L.; Kortekaas, R.; Bart, J.; Willemsen, A.T.; de Klerk, O.L.; de Vries, J.J.; van Oostrom, J.C.; Leenders, K.L. Blood-brain barrier P-glycoprotein function decreases in specific brain regions with aging: A possible role in progressive neurodegeneration. Neuro-biol. Aging, 2009, 30(11), 1818-1824.
34. Toornvliet, R.; van Berckel, B.N.M.; Luurtsema, G.; Lubberink, M.; Geldof, A.A.; Bosch, T.M.; Oerlemans, R.; Lammertsma, A.A.; Franssen, E.J.F. Effect of age on functional P-glycoprotein in the blood-brain barrier measured by use of (R)-[C-11]verapamil and positron emission tomography. Clin. Pharmacol. Ther., 2006, 79(6), 540-548.
35. Syvanen, S.; Blomquist, G.; Sprycha, M.; Hoglund, A.U.; Roman, M.; Eriksson, O.; Hammarlund-Udenaes, M.; Langstrom, B.; Bergstrom, M. Duration and degree of cyclosporin induced P-glycoprotein inhibition in the rat blood-brain barrier can be studied with PET. Neuroimage, 2006, 32(3), 1134-1141.
36. Syvanen, S.; Hooker, A.; Rahman, O.; Wilking, H.; Blomquist, G.; Langstrom, B.; Bergstrom, M.; Hammarlund-Udenaes, M. Pharmacokinetics of P-glycoprotein inhibition in the rat blood-brain barrier. J. Pharm. Sci., 2008, 97(12), 5386-5400.
37. Muzi, M.; Mankoff, D.A.; Link, J.M.; Shoner, S.; Collier, A.C.; Sasongko, L.; Unadkat, J.D. Imaging of cyclosporine inhibition of P-glycoprotein activity using 11C-verapamil in the brain: studies of healthy humans. J. Nucl. Med., 2009, 50(8), 1267-1275.
38. Bankstahl, J.P.; Kuntner, C.; Abrahim, A.; Karch, R.; Stanek, J.; Wanek, T.; Wadsak, W.; Kletter, K.; Muller, M.; Loscher, W.; Langer, O. Tariquidar-induced P-glycoprotein inhibition at the rat blood-brain barrier studied with (R)-11C-verapamil and PET. J. Nucl. Med., 2008, 49(8), 1328-1335.
39. Tsai, C.E.; Daood, M.J.; Lane, R.H.; Hansen, T.W.; Gruetz-macher, E.M.; Watchko, J.F. P-glycoprotein expression in mouse brain increases with maturation. Biol. Neonate., 2002, 81(1), 58-64.
40. Aggarwal, S.; Tsuruo, T.; Gupta, S. Altered expression and function of P-glycoprotein (170 kDa), encoded by the MDR 1 gene, in T cell subsets from aging humans. J. Clin. Immunol., 1997, 17(6), 448-454.
41. Gupta, S.; Gollapudi, S. P-glycoprotein (MDR 1 gene product) in cells of the immune system: its possible physiologic role and alteration in aging and human immunodeficiency virus-1 (HIV-1) infection. J. Clin. Immunol., 1993, 13(5), 289-301.
42. Pilarski, L.M.; Paine, D.; McElhaney, J.E.; Cass, C.E.; Belch, A.R. Multidrug transporter P-glycoprotein 170 as a differentiation antigen on normal human lymphocytes and thymocytes: modulation with differentiation stage and during aging. Am. J. Hematol., 1995, 49(4), 323-335.
43. Warrington, J.S.; Greenblatt, D.J.; Von Moltke, L.L. The effect of age on P-glycoprotein expression and function in the Fischer-344 rat. J. Pharmacol. Exp. Ther., 2004, 309(2), 730-736.
44. Salat, D.H.; Tuch, D.S.; Greve, D.N.; van der Kouwe, A.J.; Hevelone, N.D.; Zaleta, A.K.; Rosen, B.R.; Fischl, B.; Corkin, S.; Rosas, H.D.; Dale, A.M. Age-related alterations in white matter microstructure measured by diffusion tensor imaging. Neurobiol. Aging, 2005, 26(8), 1215-1227.
45. Pfefferbaum, A.; Adalsteinsson, E.; Sullivan, E.V. Frontal circuitry degradation marks healthy adult aging: Evidence from diffusion tensor imaging. Neuroimage, 2005, 26(3), 891-899.
46. Weller, R.O.; Subash, M.; Preston, S.D.; Mazanti, I.; Carare, R.O. Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer's disease. Brain Pathol., 2008, 18(2), 253-266.
47. Ueno, M.; Akiguchi, I.; Hosokawa, M.; Kotani, H.; Kanenishi, K.; Sakamoto, H. Blood-brain barrier permeability in the periventricular areas of the normal mouse brain. Acta. Neuropathol. (Berl), 2000, 99(4), 385-392.
48. Stewart, P.A.; Magliocco, M.; Hayakawa, K.; Farrell, C.L.; Del Maestro, R.F.; Girvin, J.; Kaufmann, J.C.; Vinters, H.V.; Gilbert, J. A quantitative analysis of blood-brain barrier ultrastructure in the aging human. Microvasc. Res., 1987, 33(2), 270-282.
49. Johnson, W.G. Late-onset neurodegenerative diseases-the role of protein insolubility. J. Anat., 2000, 196 (Pt 4), 609-616.
50. Lam, F.C.; Liu, R.; Lu, P.; Shapiro, A.B.; Renoir, J.M.; Sharom, F.J.; Reiner, P.B. beta-Amyloid efflux mediated by p-glycoprotein. J. Neurochem., 2001, 76(4), 1121-1128.
51. Vogelgesang, S.; Kuhnke, D.; Jedlitschky, G.; Jucker, M.; Mosyagin, I.; Pahnke, J.; Cascorbi, I.; Kroemer, H.K.; Walker, L.C.; Warzok, R.W. P-glycoprotein (ABCB1) mediates transport of Alzheimer's beta-amyloid peptides. Acta. Neuropathol., 2006, 112(3), 365-367.
52. Kuhnke, D.; Jedlitschky, G.; Grube, M.; Krohn, M.; Jucker, M.; Mosyagin, I.; Cascorbi, I.; Walker, L.C.; Kroemer, H.K.; Warzok, R.W.; Vogelgesang, S. MDR1-P-Glycoprotein (ABCB1) mediates transport of alzheimer's amyloid-beta peptides-implications for the mechanisms of abeta clearance at the blood-brain barrier. Brain Pathol., 2007.
53. Vogelgesang, S.; Cascorbi, I.; Schroeder, E.; Pahnke, J.; Kroemer, H.K.; Siegmund, W.; Kunert-Keil, C.; Walker, L.C.; Warzok, R.W. Deposition of Alzheimer's beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans. Pharmacogenetics, 2002, 12(7), 535-541.
54. Tai, L.M.; Loughlin, A.J.; Male, D.K.; Romero, I.A. P-glycoprotein and breast cancer resistance protein restrict apical-to-basolateral permeability of human brain endothelium to amyloid-beta. J. Cereb. Blood Flow Metab., 2009, 29(6), 1079-1083.
55. Vogelgesang, S.; Warzok, R.W.; Cascorbi, I.; Kunert-Keil, C.; Schroeder, E.; Kroemer, H.K.; Siegmund, W.; Walker, L.C.; Pahnke, J. The role of P-glycoprotein in cerebral amyloid angiopathy; implications for the early pathogenesis of Alzheimer's disease. Curr. Alzheimer Res., 2004, 1(2), 121-125.
56. Soffer, D. Cerebral amyloid angiopathy-a disease or age-related condition. Isr. Med. Assoc. J., 2006, 8(11), 803-806.
57. Vogelgesang, S.; Cascorbi, I.; Kroemer, H.K.; Schroeder, E.; Pahnke, J.; Siegmund, W.; Keil, C.; Warzok, R.W.; Walker, L.C. Deposition of amyloid is inversely correlated with the expression of p-glycoprotein - implications on the possibility of prevention of Alzheimer's disease. Acta Neuropathol., 2001, 102(5), 545.
58. Lee, J.M.; Markus, H.S. Does the white matter matter in Alzheimer disease and cerebral amyloid angiopathy? Neurology, 2006, 66(1), 6-7.
59. Han, X.; Holtzman, M.; McKeel, D.W. Jr.; Kelley, J.; Morris, J.C. Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer's disease: potential role in disease pathogenesis. J. Neuro-chem., 2002, 82(4), 809-818.
60. Song, S.K.; Kim, J.H.; Lin, S.J.; Brendza, R.P.; Holtzman, D.M. Diffusion tensor imaging detects age-dependent white matter changes in a transgenic mouse model with amyloid deposition. Neurobiol. Dis., 2004, 15(3), 640-647.
61. Roher, A.E.; Kuo, Y.M.; Esh, C.; Knebel, C.; Weiss, N.; Kalback, W.; Luehrs, D.C.; Childress JL, Beach TG, Weller RO, Kokjohn TA. Cortical and leptomeningeal cerebrovascular amyloid and white matter pathology in Alzheimer's disease. Mol. Med., 2003, 9(3-4):112-122.
62. Cirrito, J.R.; Deane, R.; Fagan, A.M.; Spinner, M.L.; Parsadanian, M.; Finn, M.B.; Jiang, H.; Prior, J.L.; Sagare, A.; Bales, K.R.; Paul, S.M.; Zlokovic, B.V.; Piwnica-Worms, D.; Holtzman, D.M. P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J. Clin. Invest., 2005, 115(11), 3285-3290.
63. Loeb, M.B.; Molloy, D.W.; Smieja, M.; Standish, T.; Goldsmith, C.H.; Mahony, J.; Smith, S.; Borrie, M.; Decoteau, E.; Davidson, W.;; McDougall, A.; Gnarpe, J.; O'DONNell, M.; Chernesky, M. A ran-domized, controlled trial of doxycycline and rifampin for patients with Alzheimer's disease. J. Am. Geriatr. Soc., 2004, 52(3), 381-387.
64. Fardel, O.; Lecureur, V.; Loyer, P.; Guillouzo, A. Rifampicin en-hances anti-cancer drug accumulation and activity in multi-drug-resistant cells. Biochem. Pharmacol., 1995, 49(9), 1255-1260.
65. Zong, J.; Pollack, G.M. Modulation of P-glycoprotein transport activity in the mouse blood-brain barrier by rifampin. J. Pharmacol. Exp. Ther., 2003, 306(2), 556-562.
66. Elvang, A.B.; Volbracht, C.; Pedersen, L.O.; Jensen, K.G.; Karlsson, J.J.; Larsen, S.A.; Mork, A.; Stensbol, T.B.; Bastlund, J.F. Differential effects of gamma-secretase and BACE1 inhibition on brain Abeta levels in vitro and in vivo. J. Neurochem., 2009, 10(5), 377-387.
67. Meredith, J.E. Jr.; Thompson, L.A.; Toyn, J.H.; Marcin, L.; Barten, D.M.; Marcinkeviciene, J.; Kim, Y.; Lin, A.; Guss, V.; Burton, C.; Iben, L.; Polson, C.; Cantone, J.; Ford, M.; Drexler, D.; Fiedler, T.; Lentz, K.A.; Grace, J.E. Jr.; Kolb, J.; Corsa, J.; Pierdomenico, M.; Jones, K.; Olson, R.E.; Macor, J.E.; Albright, C.F. P-glycoprotein efflux and other factors limit brain amyloid beta reduction by beta-site amyloid precursor protein-cleaving enzyme 1 inhibitors in mice. J. Pharmacol. Exp. Ther., 2008, 326(2), 502-513.
68. Hussain, I.; Hawkins, J.; Harrison, D.; Hille, C.; Wayne, G.; Cutler, L.; Buck, T.; Walter, D.; Demont, E.; Howes, C.; Naylor, A.; Jeffrey, P.; Gonzalez, M.I.; Dingwall, C.; Michel, A.; Redshaw, S.; Davis, J.B. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo. J. Neurochem., 2007, 100(3), 802-809.
69. Rajput, A.H. Environmental toxins accelerate Parkinson's disease onset. Neurology, 2001, 56(1), 4-5.
70. Caparros-Lefebvre, D.; Lees, A.J. Atypical unclassifiable parkinsonism on Guadeloupe: an environmental toxic hypothesis. Mov. Disord., 2005, 20 Suppl 12, S114-S118.
71. Davis, P.H.; Golbe, L.I.; Duvoisin, R.C.; Schoenberg, B.S. Risk factors for progressive supranuclear palsy. Neurology, 1988, 38(10), 1546-1552.
72. Bain, L.J.; LeBlanc, G.A. Interaction of structurally diverse pesticides with the human MDR1 gene product P-glycoprotein. Toxicol. Appl. Pharmacol., 1996.141(1).288-298.
73. Martel, F.; Calhau, C.; Soares-da-Silva, P.; Azevedo, I. Transport of [H-3]MPP+ in an immortalized rat brain microvessel endothelial cell line (RBE 4). Naunyn-Schmiedebergs Arch. Pharmacol., 2001, 363(1), 1-10.
74. Langston, J.W.; Forno, L.S.; Tetrud, J.; Reeves, A.G.; Kaplan, J.A.; Karluk, D. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine exposure. Annal. Neurol., 1999, 46(4), 598-605.
75. Thiruchelvam, M.; Brockel, B.J.; Richfield, E.K.; Baggs, R.B.; Cory-Slechta, D.A. Potentiated and preferential effects of combined paraquat and maneb on nigrostriatal dopamine systems: environmental risk factors for Parkinson's disease? Brain Res., 2000, 873(2), 225-234.
76. Hoffmeyer, S.; Burk, O.; von Richter, O.; Arnold, H.P.; Brock-moller, J.; Johne, A.; Cascorbi, I.; Gerloff, T.; Roots, I.; Eichel-baum, M.; Brinkmann, U. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl Acad. Sci. USA, 2000, 97(7), 3473-3478.
77. Drozdzik, M.; Bialecka, M.; Mysliwiec, K.; Honczarenko, K.; Stankiewicz, J.; Sych, Z. Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson's disease. Pharmacogenetics, 2003, 13(5), 259-263.
78. Furuno, T.; Landi, M.T.; Ceroni, M.; Caporaso, N.; Bernucci, I.; Nappi, G.; Martignoni, E.; Schaeffeler, E; Eichelbaum, M.; Schwab, M.; Zanger, U.M. Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease. Pharmacogenetics, 2002, 12(7), 529-534.
79. Zschiedrich, K.; Konig, I.R.; Bruggemann, N.; Kock, N.; Kasten, M.; Leenders, K.L.; Kostic, V.; Vieregge, P.; Ziegler, A.; Klein, C.; Lohmann, K.MDR1 variants and risk of Parkinson disease. Association with pesticide exposure.? J. Neurol., 2009, 256(1), 115-120.
80. Morita, N.; Yasumori, T.; Nakayama, K. Human MDR1 polymorphism: G2677T/A and C3435T have no effect on MDR1 transport activities. Biochem. Pharmacol., 2003, 65(11), 1843-1852.
81. Braak, H.; Braak, E. Pathoanatomy of Parkinson's disease. J. Neurol., 2000, 247, 3-10.
82. Yokel RA. Blood-brain barrier flux of aluminum, manganese, iron and other metals suspected to contribute to metal-induced neurodegeneration. J. Alzheimers Dis., 2006, 10(2-3), 223-253.
83. Graff CL, Pollack GM. Functional evidence for P-glycoprotein at the nose-brain barrier. Pharm. Res., 2005, 22(1), 86-93.
84. Kandimalla KK, Donovan MD. Localization and differential activity of P-glycoprotein in the bovine olfactory and nasal respiratory mucosae. Pharm. Res., 2005, 22(7), 1121-1128.
85. Kortekaas, R.; Leenders, K. L.; van Oostrom, J.C.H.; Vaalburg, W.; Bart, J.; Willemsen, A.T.M.; Hendrikse, N.H. Blood-brain barrier dysfunction in Parkinsonian midbrain in vivo. Ann. Neurol., 2005, 57(2), 176-179.
86. Bartels, A.L.; van Berckel, B.N.; Lubberink, M.; Luurtsema, G.; Lammertsma, A.A.; Leenders, K.L. Blood-brain barrier P-glyco-protein function is not impaired in early Parkinson's disease. Parkinsonism Relat. Disord., 2008, 14(6), 505-508.
87. Bartels, A.L.; Willemsen, A.T.; Kortekaas, R.; de Jong, B.M.; de VR, de KO, van Oostrom JC, Portman A, Leenders KL. De-creased blood-brain barrier P-glycoprotein function in the pro-gression of Parkinson's disease, PSP and MSA. J. Neural. Transm., 2008, 115(7), 1001-1019.
88. Green, J.; McDonald, W.M.; Vitek, J.L.; Evatt, M.; Freeman, A.; Haber, M.; Bakay, R.A.; Triche, S.; Sirockman, B.; DeLong, M.R. Cognitive impairments in advanced PD without dementia. Neurology, 2002, 59(9), 1320-1324.
89. Vogelgesang, S.; Glatzel, M.; Walker, L.C.; Kroemer, H.K.; Aguzzi, A.; Warzok, R.W. Cerebrovascular P-glycoprotein expression is decreased in Creutzfeldt-Jakob disease. Acta Neuropathol. (Berl), 2006, 111(5), 436-443.
90. Begley, G.S.; Horvath, A.R.; Taylor, J.C.; Higgins, C.F. Cytoplasmic domains of the transporter associated with antigen processing and P-glycoprotein interact with subunits of the proteasome. Mol. Immunol., 2005, 42(1), 137-141.
91. Norris, E.H.; Uryu, K.; Leight, S.; Giasson, B.I.; Trojanowski, J.Q.; Lee, V.M. Pesticide exposure exacerbates alpha-synucleinopathy in an A53T transgenic mouse model. Am. J. Pathol., 2007, 170(2), 658-666.
92. Burn, D. J. Parkinson's disease dementia: what's in a Lewy body? J. Neural. Transm., (Suppl) 2006, (70), 361-365.
93. Soares-da-Silva, P.; Serrao, M.P. Outward transfer of dopamine precursor L-3, 4-dihydroxyphenylalanine (L-dopa) by native and human P-glycoprotein in LLC-PK(1) and LLC-GA5 col300 renal cells. J. Pharmacol. Exp. Ther., 2000, 293(2), 697-704.
94. Uhr, M.; Ebinger, M.; Rosenhagen, M.C.; Grauer, M.T. The antiParkinson drug budipine is exported actively out of the brain by P-glycoprotein in mice. Neurosci. Lett., 2005, 383(1-2), 73-76.
95. Zahodne, L.B.; Fernandez, H.H. Pathophysiology and treatment of psychosis in Parkinson's disease: a review. Drugs Aging, 2008, 25(8), 665-682.
96. Ezzi, S.A.; Urushitani, M.; Julien, J.P. Wild-type superoxide dismu-tase acquires binding and toxic properties of ALS-linked mutant forms through oxidation. J. Neurochem., 2007, 102(1), 170-178.
97. Bensimon, G.; Lacomblez, L.; Meininger, V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N. Engl. J. Med., 1994, 330(9), 585-591.
98. Milane, A.; Fernandez, C.; Vautier, S.; Bensimon, G.; Meininger, V.; Farinotti, R. Minocycline and riluzole brain disposition: interactions with p-glycoprotein at the blood-brain barrier. J. Neurochem., 2007, 103(1), 164-173.
99. Milane, A.; Tortolano, L.; Fernandez, C.; Bensimon, G.; Meininger, V.; Farinotti, R. Brain and plasma riluzole pharmacokinetics: effect of minocycline combination. J. Pharm. Pharm. Sci., 2009, 12(2), 209-217.
100. Hampel, H.; Muller-Spahn, F.; Berger, C.; Haberl, A.; Ackenheil, M.; Hock, C. Evidence of blood-cerebrospinal fluid-barrier impairment in a subgroup of patients with dementia of the Alzheimer type and major depression: a possible indicator for immunoactivation. Dementia, 1995, 6(6), 348-354.
101. Hampel, H.; Kotter, H.U.; Moller, H.J. Blood-cerebrospinal fluid barrier dysfunction for high molecular weight proteins in Alzheimer disease and major depression: Indication for disease subsets. Alz-heimer Dis. Assoc. Disord., 1997, 11(2), 78-87.
102. de Klerk, O.L.; Willemsen, A.T.; Roosink, M.; Bartels, A.L.; Harry, H.N.; Bosker, F.J.; den Boer, J.A. Locally increased P-glycoprotein function in major depression: a PET study with [11C]verapamil as a probe for P-glycoprotein function in the blood-brain barrier. Int. J. Neuropsychopharmacol., 2009, 1-10.
103. Feng, B.; Mills, J.B.; Davidson, R.E.; Mireles, R.J.; Janiszewski, J.S.; Troutman, M.D.; de Morais, S.M. In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system. Drug Metab. Dispos., 2008, 36(2), 268-275.
104. Wang, J.S.; Zhu, H.J.; Gibson, B. B.; Markowitz, J.S.; Donovan, J.L.; DeVane, C.L. Sertraline and its metabolite desmethylsertraline, but not bupropion or its three major metabolites, have high affinity for P-glycoprotein. Biol. Pharm. Bull., 2008, 31(2), 231-234.
105. Linnet, K.; Ejsing, T. B. A review on the impact of P-glycoprotein on the penetration of drugs into the brain. Focus on psychotropic drugs. Eur. Neuropsychopharmacol., 2008, 18(3), 157-169.
106. Maines, L.W.; Antonetti, D.A.; Wolpert, E.B.; Smith, C.D. Evaluation of the role of P-glycoprotein in the uptake of paroxetine, clozapine, phenytoin and carbamazapine by bovine retinal endothelial cells. Neuropharmacology, 2005, 49(5), 610-617.
107. Schinkel, A.H.; Wagenaar, E.; Mol, C.A.; van Deemter, L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J. Clin. In-vest., 1996, 97(11), 2517-2524.
108. Uhr, M.; Grauer, M.T.; Holsboer, F. Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption. Biol. Psychiatry, 2003, 54(8), 840-846.
109. Grauer, M.T.; Uhr, M. P-glycoprotein reduces the ability of amitriptyline metabolites to cross the blood brain barrier in mice after a 10-day administration of amitriptyline. J. Psychopharmacol., 2004, 18(1), 66-74.
110. de Klerk, O.L.; Bosker, F.J.; Willemsen, A.T.; van Waarde, A.; Visser, A.K.; de Jager, T.; Dagyte, G.; den Boer, J.A.; Dierckx, R.A.; Meerlo, P. Chronic stress and antidepressant treatment have opposite effects on P-glycoprotein at the blood-brain barrier: an experimental PET study in rats. J. Psychopharmacol., 2009 [Epub ahead of print].